Servier buys oncology business from Shire

| By | Cancer Drugs, Pharmaceutical Deal, Servier, Shire
0
473

Shire, the leading global biotechnology company focused on rare diseases announced that it has entered into a definitive agreement with to sell its Oncology business for $2.4 billion.

Shire’s Oncology business includes in-market products ONCASPAR® (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-U.S. rights to ONIVYDE® (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL and early stage immuno-oncology pipeline collaborations.

Shire’s Board of Directors initiated the potential divestment of the Oncology business in December 2017. The process, which commenced in January 2018, identified multiple potential strategic buyers across the U.S., Europe and Japan. The deal is expected to close in the second or third quarter of 2018.

SOURCE: shire
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.